🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Vivodyne, a startup developing a new bio-pharma discovery pipeline that starts and ends in lab-grown human tissues, is pleased to announce that it has raised $4 million in seed funding from Kairos Ventures. kairosventures.com/vivodyne-is-th… #Vivodyne #biopharma

Venture Capital Journal: "Biopharma startup Vivodyne pulls in $4m seed" venturecapitaljournal.com/biopharma-star…

Congrats to Mark, Dan, and team for such great work. This model goes a long way to helping uncover therapies for wasting disorders like cachexia. blog.seas.upenn.edu/penn-engineeri…

Vivodyne Named #1 in Fast Company’s Annual List of the World’s Most Innovative “Small but Mighty” Companies for 2022... link.medium.com/cdHFcoSCeob

Vivodyne Announces Dr. Anthony Bahinski as its new Chief Technology Officer link.medium.com/TZSTY4V9Mob

Dr. Jane Goodall of the Jane Goodall Institute and Vivodyne today announced that they have delivered a letter to Congress urging its inclusion of the FDA Modernization Act of 2021 as a rider on FDA User Fee Package. #OrganChips #NAMs #FDAModernizationAct linkedin.com/posts/vivodyne…

Dr. Jane Goodall and Vivodyne Issue Open Letter to Congressional Leaders to Include FDA Modernization Act as a Rider in the Food and Drug Amendments Act of 2022 yahoo.com/now/dr-jane-go…

Great news! The FDA Modernization Act has passed in the Senate with unanimous bipartisan approval. prnewswire.com/news-releases/…

We're thrilled to announce that Dr. Susan Billings has joined the Vivodyne team as our Chief Commercial Officer. medium.com/p/bc414ee316fb

#Vivodyne lands $38m to predict drug effects using lab-grown organs... Khosla Ventures leads round for Vivodyne #AI platform that enables generation of predictive human data before therapies enter clinical trials. longevity.technology/news/vivodyne-… #longevity #investment #drugdevelopment

Khosla Ventures-backed Vivodyne is growing human tissues in the lab to test potential new therapies before they go to clinical trials. go.forbes.com/c/RZKC

.Vivodyne's Lab Grown Human Tissue Platform Gets Real with $38 Million Seed Financing Vivodyne’s #AI driven platform is used to discover and develop drugs by testing directly on lab-grown human organ tissues. Learn more: ow.ly/69zN50QalZv

We're proud to announce a major milestone in our company's growth, as we continue our mission to advance the quality and pace of therapeutics discovery. Excited to be joined by Khosla Ventures, Kairos Ventures, CS Ventures, MBX Capital, & Bison Ventures. forbes.com/sites/alexknap…

We’re excited to announce the appointment of Julie O’Shaughnessy as Vivodyne’s Chief Operating Officer! businesswire.com/news/home/2024…

"We want to be able to do in human tissue what we do in mice, which is we reiterate and refine." Andrei Georgescu, Ph.D., Vivodyne cofounder and CEO, spoke about drug discovery at the 2024 Forbes Healthcare Summit. #ForbesHealth forbes.com/connect/event/…

Right way to go for screening biology against therapeutics. Massive improvement in scaling on way to building AI scientists for biology.